C.R. Bard
http://www.crbard.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From C.R. Bard
Samsung Bioepis Aims To Compete On Higher-Strength Humira In US
Samsung Bioepis and Organon have revealed plans to compete with higher-concentration formulations of adalimumab in the US, after the FDA accepted for review an sBLA for a citrate-free 100mg/ml version of the SB5 Hadlima biosimilar that is already approved in a 50mg/ml formulation.
Investment Set To Rise, Non-COVID R&D To Normalize As Korean Pharma Looks Ahead To 2022
Scrip takes a look back at the milestone events in the South Korean pharma and biotech industry in 2021 and ahead at what's in store for the coming year, which has kicked off with speculation around a major potential M&A deal.
Samsung Bioepis Celebrates Soliris Success
Samsung Bioepis has revealed positive Phase I trial results for its SB12 proposed eculizumab biosimilar rival to Soliris.
How Samsung Bioepis Is Laying A Path For Ophthalmic Biosimilars
With the first approved rival to Lucentis in both the EU and US, Samsung Bioepis is laying the groundwork for biosimilars to break into ophthalmology ahead of launching its Byooviz version of ranibizumab, explains vice-president of commercial strategy Josh Lee.
Company Information
- Industry
- Medical Devices
- Other Names / Subsidiaries
-
- Davol, Inc.
- Embo Medical Limited
- Liberator Medical, Inc.
- Lutonix, Inc.
- Medafor, Inc.
- Medicon, Inc.
- Neomend, Inc.
- Rochester Medical, Inc.
- Vascular Pathways, Inc.
- FlowCardia, Inc.
- Bridger Biomed, Inc.